News
09-02-2013, 02:27 AM
Halozyme Therapeutics, Inc. announced today that the European Commission has granted Roche European Union marketing authorization for the use of a time-saving subcutaneous formulation of Herceptin (trastuzumab) for the treatment of HER2-positive breast cancer.
More... (http://www.news-medical.net/news/20130902/Roches-Herceptin-formulation-wins-EU-approval-for-treatment-of-HER2-positive-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20130902/Roches-Herceptin-formulation-wins-EU-approval-for-treatment-of-HER2-positive-breast-cancer.aspx)